Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
<p><strong>Introduction: </strong>Pain is a multidimensional factor and core domain of psoriatic arthritis (PsA). This analysis aimed to quantify the role of potential inflammation-associated outcomes on pain reduction in patients with PsA receiving tofacitinib, using medi...
Principais autores: | de Vlam, K, Mease, PJ, Bushmakin, AG, Fleischmann, R, Ogdie, A, Azevedo, VF, Merola, JF, Woolcott, J, Cappelleri, JC, Fallon, L, Taylor, PC |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Springer
2022
|
Registros relacionados
-
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, K, et al.
Publicado em: (2021) -
Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
por: Taylor, PC, et al.
Publicado em: (2020) -
Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
por: Taylor, P, et al.
Publicado em: (2019) -
Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, K, et al.
Publicado em: (2018) -
Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
por: Ogdie, A, et al.
Publicado em: (2018)